Avalo Therapeutics (AVTX)

• Market cap: $336M
• 1 day: -2.32%
• 5 days: 3.34%
• 1 month: 3.11%
• 3 months: 95.26%
• 6 months: 412.43%
• Year to date: 120.05%
• 1 year: 85.69%
• 5 years: -99.74%
• 10 years: -99.85%
• Sector: Healthcare
• Industry: Biotechnology

About: Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Employees: 23